DEA Hands Dipentylone Its Own VIP Spot on the Naughty Drug List
Published Date: 8/8/2025
Rule
Summary
The DEA is giving dipentylone its own official spot on the list of the most tightly controlled drugs (Schedule I). This means dipentylone is now clearly recognized and tracked separately from similar drugs. People who make, sell, or use this drug will need to follow these updated rules right away, but there’s no new cost involved.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Dipentylone Added to Schedule I
The DEA has added 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one (dipentylone; N,N-dimethylpentylone) as a separately listed Schedule I controlled substance with its own DEA drug code. Dipentylone is now explicitly listed apart from its positional isomer N-ethylpenthylone (which was controlled on August 31, 2018). People who make, sell, or possess dipentylone must follow the Schedule I rules right away, and the rule says there is no new financial cost involved.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-15143, Safety Zone; Gulf of America; Sand Key Beach, Clearwater, FL
The Coast Guard is setting up a temporary safety zone at Sand Key Beach in Clearwater, FL, during the Clearwater AquaX Grand Prix jet ski race. This means boats and people can’t enter the area unless they get special permission, keeping everyone safe during the high-speed event. The safety zone is only active during the race, so plan ahead if you’re nearby!
Next: C1-2025-13893, Air Plan Approval; Pennsylvania; Redesignation Request and Associated Maintenance Plan for the Liberty-Clairton Area for the 1997 Annual and 2006 24-Hour Fine Particulate Matter Standard and Maintenance Plan for the Allegheny County Area for the 2012 Annual Fine Particulate Matter Standard
Pennsylvania’s Liberty-Clairton and Allegheny County areas are officially recognized as meeting important air quality standards for tiny particle pollution. This update fixes some dates to July 24, 2025, ensuring the state’s plans to keep the air clean stay on track. Residents and local businesses can breathe easier knowing these improvements are locked in without extra costs or delays.